HIV Waiting Room

Test Your Skills in Managing These Patients

Clinical Practice Guidelines

Recommendations for evaluation and management of bone disease in HIV.

Brown TT, Hoy J, Borderi M, et al. Clin Infect Dis. 2015;60(8):1242-1251.

Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People.

Coleman E, Bockting W, Botzer M, et al. 7th ed. East Dundee, Illinois: World Professional Association for Transgender Health.

Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel.

Saag MS, Benson CA, Gandhi RT, et al. JAMA. 2018;320(4):379-396.

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV.

US Department of Health and Human Services

Guidelines for Managing Advanced HIV Disease and Rapid Initiation of Antiretroviral Therapy.

World Health Organization

Patient and Caregiver Resources

AIDSMap Resources

NAM Publications

Resources for persons living with HIV

Centers for Disease Control and Prevention

HIV Resources

National Institutes of Health

Fenway Health

UCSF Transgender Care

University of California San Francisco

Suggested Readings

Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.

Aboud M, Orkin C, Podzamczer D, et al. Lancet HIV. 2019;6(9):e576-e587.

Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps.

Boyd MA, Boffito M, Castagna A, Estrada V. HIV Med. 2019;20(suppl 1):3-11.

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.

Daar ES, DeJesus E, Ruane P, et al. Lancet HIV. 2018;5(7):e347-e356.

HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable.

Eisinger RW, Dieffenbach CW, Fauci AS. JAMA. 2019;321(5):451-452.

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.

Eron JJ, Orkin C, Cunningham D, et al. Antiviral Res. 2019;170:104543.

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.

Gallant JE, Daar ES, Raffi F, et al. Lancet HIV. 2016;3(4):e158-e165.

Immediate versus deferred switching from a boosted protease inhibitor-based regimen to a dolutegravir-based regimen in virologically suppressed patients with high cardiovascular risk or age ≥50 years: final 96‑week results of the NEAT022 study.

Gatell JM, Assoumou L, Moyle G, et al. Clin Infect Dis. 2019;68(4):597-606.

Cross-sex hormones and acute cardiovascular events in transgender persons: a cohort study.

Getahun D, Nash R, Flanders WD, et al. Ann Intern Med. 2018;169(4):205-213.

Sexualized drug use (chemsex) is associated with high-risk sexual behaviors and sexually transmitted infections in HIV-positive men who have sex with men: data from the U-SEX GESIDA 9416 study.

González-Baeza A, Dolengevich-Segal H, Pérez-Valero I, et al; the U-SEX GESIDA 9416 Study. AIDS Patient Care STDS. 2018;32(3):112-118.

Human immunodeficiency virus and trans women: a literature review.

Jaspal R, Kennedy L, Tariq S. Transgend Health. 2018;3(1):239-250.

Switching to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT Trial.

Johnson M, Kumar P, Molina JM, et al; for the DRIVE-SHIFT Study Group. J Acquir Immune Defic Syndr. 2019;81(4):463-472.

Cross-sectional analysis of chemsex drug use and gonorrhoea diagnosis among men who have sex with men in the UK.

Kohli M, Hickson F, Free C, Reid D, Weatherburn P. Sex Health. 2019;16(5):464-472.

HIV among black men who have sex with men (MSM) in the United States: a review of the literature.

Maulsby C, Millett G, Lindsey K, et al. AIDS Behav. 2014;18(1):10-25.

Factors associated with antiretroviral therapy adherence among transgender women receiving HIV medical care in the United States.

Mizuno Y, Beer L, Huang P, Frazier EL. LGBT Health. 2017;4(3):181-187.

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

Molina JM, Ward D, Brar I, et al. Lancet HIV. 2018;5(7):e357-e365.

The effect of same-day observed initiation of antiretroviral therapy on HIV viral load and treatment outcomes in a US public health setting.

Pilcher CD, Ospina-Norvell C, Dasgupta A, et al. J Acquir Immune Defic Syndr. 2017;74(1):44-51.

Global epidemiology of HIV infection and related syndemics affecting transgender people.

Poteat T, Scheim A, Xavier J, Reisner S, Baral S. J Acquir Immune Defic Syndr. 2016;72(suppl 3):S210-219.

Dual therapy with darunavir and ritonavir plus lamivudine vs triple therapy with darunavir and ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine for maintenance of human immunodeficiency virus type 1 viral suppression: randomized, open-label, noninferiority DUAL-GESIDA 8014-RIS-EST45 trial.

Pulido F, Ribera E, Lagarde M, et al; for the DUAL-GESIDA-8014-RIS-EST45 Study Group. Clin Infect Dis. 2017;65(12):2112-2118.

Transgender women, hormonal therapy and HIV treatment: a comprehensive review of the literature and recommendations for best practices.

Radix A, Sevelius J, Deutsch MB. J Int AIDS Soc. 2016;19(3 suppl 2):20810.

Switching antiretroviral regimes for the treatment of HIV: safety implications.

Utrillo L, Vidal F, Puig T, Domingo P. Expert Opin Drug Saf. 2016;15(10):1349-1360.

HIV Waiting Room: Newly diagnosed transgender woman

Test Your Skills in Managing These Patients

HIV Waiting Room: Newly diagnosed young MSM with a history of recreational drug use

Test Your Skills in Managing These Patients

HIV Waiting Room: Well-informed, HIV treatment-experienced patient looking for updates on switching regimens and emerging approaches to treatment

Test Your Skills in Managing These Patients

Relevant Resources

PrEP for Your Patients’ Needs

The PCPs Role in Preventing HIV


Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV

Value-Based HIV Formularies

Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care

Hepatitis C is Curable

Got it? Treat it!

Real-World Issues in HIV Prevention & Treatment

The Critical Role of the Community Pharmacist


Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.

Evolving Models of HIV Care

Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box

Updates in HCV Screening and Treatment

Key Issues Impacting OB/GYN Practice

Clinical Issues in Chronic Liver Disease

Hot Topics in HBV, HCV, and NASH

Evolving Models of HIV Care

Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice

Assessing Your Patients for HCV and HIV

Why It Matters in OB/GYN Practice Today

HIV as a Chronic Disease

A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities

The Pursuit of Hepatitis C Elimination

How the Pharmacist Can Make a Difference

Trends in Infectious Diseases: Updates on Treatment & Prevention Strategies for HIV and HCV

Understanding the Growing Syndemic — Opioids, HCV, and HIV

Stepping Up to the Challenge

The PCP’s Role in HCV Elimination

The Changing Landscape of HIV Prevention

What the Pharmacist Needs to Know about PrEP

HIV Updates for Pharmacy Practice

Maximizing Your Role to Impact Patient Outcomes